Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis

Simple item page
dc.check.date2025-11-29en
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisheren
dc.contributor.authorO'Mahony, A. T.en
dc.contributor.authorWaldron, M. G.en
dc.contributor.authorHenry, P. J.en
dc.contributor.authorShet, Sahilen
dc.contributor.authorO'Regan, P. W.en
dc.contributor.authorBennett, D. M.en
dc.contributor.authorRyan, D. J.en
dc.contributor.authorMaher, M. M.en
dc.contributor.authorHenry, M. T.en
dc.date.accessioned2025-01-15T12:35:32Z
dc.date.available2025-01-15T12:35:32Z
dc.date.issued2024-11-29en
dc.description.abstractAIM: Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease. Changes in body composition potentially correlate with outcomes in patients with IPF. MATERIALS AND METHODS: Patients with IPF on antifibrotic treatment attending a single institution were identified and retrospectively evaluated (n=84). Three groups were formed based on antifibrotic treatment: pirfenidone group, nintedanib group and pirfenidone-nintedanib switch group. Morphomic analysis of muscle quantity (cross-sectional area in cm2) and quality (density in Hounsfield Units) on thoracic computed tomography (CT) was performed using a web-based morphomic segmentation tool. Bilateral erector spinae and pectoralis muscles were measured at pre-defined vertebral levels. RESULTS: All three treatment groups showed a statistically significant decline in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), pectoral muscle cross sectional area (PMA), and erector spinae muscle cross-sectional area (ESMA). Muscle density did not change significantly. Differences existed in analytic morphomics between treatment groups. Patients with a pretreatment body mass index (BMI) below 30 were found to have a significantly greater loss of PMA when treated with nintedanib instead of pirfenidone. FVC and DLCO did not differ between treatment groups. CONCLUSION: There were no direct correlations between pulmonary function and morphomic parameters in our entire group of IPF patients. However, between different treatment groups, the rate of muscle bulk loss differed. This is an important consideration for clinicians when deciding on an antifibrotic agent of choice.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid106759en
dc.identifier.citationO'Mahony, A. T., Waldron, M. G., Henry, P. J., Shet, S., O'Regan, P. W., Bennett, D. M., Ryan, D. J., Maher, M. M. and Henry, M. T. (2025) 'Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis', Clinical Radiology, 81, 106759 (8pp). https://doi.org/10.1016/j.crad.2024.106759en
dc.identifier.doihttps://doi.org/10.1016/j.crad.2024.106759en
dc.identifier.endpage8en
dc.identifier.issn0009-9260en
dc.identifier.journaltitleClinical Radiologyen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/16828
dc.identifier.volume81en
dc.language.isoenen
dc.publisherElsevier Ltd.en
dc.relation.ispartofClinical Radiologyen
dc.rights© 2024, The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectPulmonary functionen
dc.subjectIdiopathic pulmonary fibrosisen
dc.subjectMuscle bulk lossen
dc.subjectAntifibrotic agenten
dc.titleComputed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosisen
dc.typeArticle (peer-reviewed)en
oaire.citation.volume81en
Files
Original bundle
Now showing 1 - 5 of 5
Thumbnail Image
Name:
Blinded Manuscript IPF SS with revisions 06.11 (1).pdf
Size:
353.1 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Thumbnail Image
Name:
Blinded Manuscript IPF SS with revisions 06.11 (1).docx
Size:
38.31 KB
Format:
Microsoft Word XML
Description:
Authors' original accepted version
Thumbnail Image
Name:
mmc2.docx
Size:
15.57 KB
Format:
Microsoft Word XML
Description:
Multimedia component 2
Thumbnail Image
Name:
mmc3.docx
Size:
14.09 KB
Format:
Microsoft Word XML
Description:
Multimedia component 3
Thumbnail Image
Name:
mmc1.docx
Size:
16.27 KB
Format:
Microsoft Word XML
Description:
Multimedia component 1
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles